

National Health Investors Inc (NHI)

Updated May 18th, 2023 by Quinn Mohammed

Key Metrics

Current Price:	\$53	5 Year CAGR Estimate:	10.8%	Market Cap:	\$2.3 B
Fair Value Price:	\$57	5 Year Growth Estimate:	4.0%	Ex-Dividend Date1:	06/29/2023
% Fair Value:	92%	5 Year Valuation Multiple Estimate:	1.6%	Dividend Payment Date1:	08/04/2023
Dividend Yield:	6.8%	5 Year Price Target	\$69	Years Of Dividend Growth:	0
Dividend Risk Score:	D	Retirement Suitability Score:	В	Rating:	Buy

Overview & Current Events

National Health Investors is an REIT focused on healthcare facilities. Some of the healthcare facilities NHI invests in are independent living facilities, senior-living campuses, and medical office buildings. NHI specializes in sale-leaseback, joint-venture, mortgage, and mezzanine financing. The company was incorporated in 1991 and is headquartered in Tennessee. National Health Investors raised its dividend for 19 years, but then slashed it in 2021. This healthcare facility REIT has a market capitalization of \$2.3 billion.

On March 31st, 2022, NHI had investments in 98 senior housing properties, 65 skilled nursing facilities, and one hospital across 31 states. During 2022, rental income was \$218 million and made up 78% of income.

On May 9th, 2023, National Health Investors reported first quarter 2023 results. Normalized FFO per diluted common share for the quarter was \$1.11, a penny increase from \$1.10 in the prior year quarter.

NHI purchased a 64-unit assisted living and memory care complex in Chesapeake, Virginia, from Bickford in February 2023. It also acquired two memory care facilities run by Silverado Senior Living, which each include a 60-unit community. The company has also sold five assisted living communities year-to-date to optimize the portfolio.

National Health Investors upgraded normalized FFO guidance and now expects \$4.37 to \$4.42 (compared to \$4.24 to \$4.30 previously) for FY 2023.

Growth on a Per-Share Basis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
AFFOPS	\$3.43	\$3.75	\$4.10	\$4.39	\$4.75	\$5.04	\$5.10	\$5.29	\$4.60	\$4.30	\$4.39	\$5.34
DPS	\$3.12	\$3.08	\$3.40	\$3.60	\$3.80	\$4.00	\$4.20	\$4.41	\$4.01	\$3.60	\$3.60	<i>\$3.78</i>
Shares ²	28.4	33.4	37.6	39.2	41.2	42.1	43.7	44.7	45.7	43.4	43.5	50.0

National Health Investors has been able to generate a stream of fairly predictable and consistent adjusted funds from operations (AFFO). In the last 9 years AFFO has grown by 2.5% on average, but this has slowed in recent years and resulted in a 5-year AFFO growth rate of -2.0%.

Shares outstanding have grown by nearly 5% annually over the last decade, which is somewhat normal for an REIT. The number of shares being issued is not outrageous, but makes it more difficult to grow AFFO on a per-share basis.

Increased investment activity through financing or purchasing more healthcare real estate, as well as improved collections, and improved occupancies should see NHI continue to grow. We are forecasting 4.0% average annual AFFO growth over the intermediate term.

The corporation will pursue acquisitions and diversify opportunistically, with the main focus on triple-net senior housing and skilled nursing. The company expects to further diversify across asset, tenant, and geography. National Health has paid special dividends a few times in the past, most recently in 2011 and 2013. With the 2021 dividend cut, we estimate that NHI will potentially resume growing the dividend at no more than 1% to maintain flexibility in the following years.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.

¹ Estimate

² In millions



National Health Investors Inc (NHI)

Updated May 18th, 2023 by Quinn Mohammed

Valuation Analysis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	Now	2028
Avg. P/AFFO	18.0	16.6	15.8	16.2	16.0	14.4	15.7	12.1	14.0	13.5	12.0	13.0
Avg. Yld.	4.5%	4.8%	5.0%	4.9%	4.8%	5.4%	5.1%	6.6%	6.4%	6.1%	6.8%	5.4%

National Health Investors has traded at a P/E ratio of 15.2 on average in the past nine years, and 13.9 on average in the past five years. While shares trade at 12.0 times estimated 2023 AFFO, we believe fair value is 13.0 times AFFO, which could lead to a 1.6% annual gain due to valuation expansion.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
Payout	91%	82%	83%	82%	80%	79%	82%	83%	87%	84%	82%	71%


While NHI does not have a strong competitive advantage over other healthcare REITs, the corporation believes that they have an advantage in accessing debt markets due to a strong balance sheet. The company is highly diversified across tenant, geography and asset type which is also advantageous. During the great recession, share price did not fall as much as the overall market, and in fact, FFO per share grew from 2008 to 2010.

Target leverage is set at 4x - 5x Net Debt to Adjusted Annualized EBITDA, and the company targets a 60/40 equity/debt funding mix. At the end of Q1 2023, NHI's leverage ratio was 4.6X, within target range. While the payout ratio appeared to be stable in the last few years, NHI still opted to preemptively slash the dividend in 2021, thus we would not rely on it to consistently grow the dividend from here on out.

Final Thoughts & Recommendation

While National Health Investors has a history of performing well, weak occupancy and problems with specific, large partners led the company to sell a meaningful portion of their properties recently. The corporation trades below our estimated fair value, and has expected annualized total returns of 10.8%, the majority of which come from the 6.8% yield. NHI thus earns a buy rating.

Total Return Breakdown by Year



Click here to rate and review this research report. Your feedback is important to us.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



National Health Investors Inc (NHI)

Updated May 18th, 2023 by Quinn Mohammed

Income Statement Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Revenue	118	178	229	248	279	295	318	333	299	278
Gross Profit					279	295	312	323	287	268
Gross Margin	0.0%	0.0%	0.0%	0.0%	100.0%	100.0%	98.2%	97.1%	96.1%	96.5%
SG&A Exp.	10	9	11	10	13	13	14	15	19	25
D&A Exp.	21	41	57	63	67	71	77	83	81	71
Operating Profit	87	130	164	178	198	204	220	225	186	143
Operating Margin	74.0%	73.0%	71.6%	71.5%	71.0%	69.3%	69.2%	67.6%	62.3%	51.5%
Net Profit	106	102	149	152	159	154	160	185	112	66
Net Margin	90.1%	57.2%	65.0%	61.0%	57.2%	52.4%	50.4%	55.6%	37.4%	23.9%
Free Cash Flow	104	126	164	177	198	208	241	232	211	185

Balance Sheet Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Total Assets	1,456	1,983	2,133	2,404	2,546	2,751	3,042	3,120	2,839	2,507
Cash & Equivalents	11	3	13	5	3	5	5	43	37	19
Accounts Receivable	21	39	63	82	100	112	89	98	99	82
Total Liabilities	679	933	991	1,194	1,224	1,361	1,544	1,598	1,322	1,218
Accounts Payable	8	16	20	21	16	20	26	25	23	26
Long-Term Debt	617	863	914	1,116	1,145	1,282	1,440	1,499	1,243	1,148
Shareholder's Equity	767	1,040	1,133	1,210	1,322	1,390	1,498	1,512	1,507	1,270
LTD/E Ratio	0.81	0.83	0.81	0.92	0.87	0.92	0.96	0.99	0.82	0.90

Profitability & Per Share Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Return on Assets	9.8%	5.9%	7.2%	6.7%	6.4%	5.8%	5.5%	6.0%	3.8%	2.5%
Return on Equity	17.4%	11.2%	13.7%	12.9%	12.6%	11.4%	11.1%	12.3%	7.4%	4.8%
ROIC	10.3%	6.1%	7.5%	6.9%	6.6%	6.0%	5.7%	6.2%	3.9%	2.6%
Shares Out.	28.4	33.4	37.6	39.2	41.2	42.1	43.7	44.7	45.7	44.8
Revenue/Share	4.15	5.31	6.08	6.35	6.77	7.00	7.28	7.45	6.53	6.21
FCF/Share	3.67	3.77	4.37	4.51	4.81	4.94	5.51	5.19	4.61	4.14

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.